RMD - ResMed Inc.

NYSE - Nasdaq Real Time Price. Currency in USD

114.44

+0.96 (+0.85%)

As of 2:00PM EDT. Market open.

Stock chart is not supported by your current browser

Previous Close	113.48
Open	113.67
Bid	114.29 x 800
Ask	114.32 x 1000
Day's Range	113.61 - 114.85
52 Week Range	75.28 - 114.85
Volume	386,329
Avg. Volume	686,104

Market Cap	16.335B
Beta	1.21
PE Ratio (TTM)	52.26
EPS (TTM)	2.19
Earnings Date	Oct 24, 2018 - Oct 29, 2018
Forward Dividend & Yield	1.48 (1.30%)
Ex-Dividend Date	2018-08-15
1y Target Est	104.69

Trade prices are not sourced from all markets

All

News

Press Releases

Zacks3 days ago
ResMed Unveils AirFit F30, Expands AirFit Mask Portfolio
ResMed's (RMD) recent product launches will strengthen its position in the high-potential sleep-disordered breathing market.
Business Wire3 days ago
175 Million Europeans Have Sleep Apnoea, Highlighting Scale of Global Health Crisis
Roughly 175 million Europeans have obstructive sleep apnoea, according to a late-breaking abstract presented by ResMed today at the European Respiratory Society’s annual ERS Congress in Paris. Leading researchers estimate 90 million Europeans have moderate to severe sleep apnoea, meaning they experience at least 15 breathing events an hour during sleep. These statistics are based on the latest scoring rules for determining one’s apnoea–hypopnoea index (AASM 2012) and are connected with a 16-country study announced in May 2018 that revealed an estimated 936 million people worldwide have sleep apnoea, a chronic sleep-disordered breathing condition associated with increased risk of mortality and reduced quality of life.
Business Wire8 days ago
ResMed Introduces Its First Minimal-contact Full Face CPAP Mask, AirFit F30
AirFit F30 outperforms leading mask of its kind in fit, seal, ease of use
GuruFocus.com10 days ago
5 Companies Hit 52-Week Highs
According to GuruFocus list of 52-week highs , these Guru stocks have reached their 52-week highs. Warning! GuruFocus has detected 4 Warning Sign with COL. Rockwell Collins Inc. is an aviation and high-integrity solutions company serving commercial and military customers.
Reuters11 days ago
NZ's Fisher & Paykel Healthcare files complaint in the U.S. against Resmed
Medical device maker Fisher & Paykel Healthcare said on Tuesday it had filed a patent infringement complaint against California-based Resmed, alleging it infringed five of its patents related to sleep apnea devices. The company said in a statement that it sought an exclusion order from the U.S. International Trade Commission (ITC) to prevent the importation and sale of Resmed's AirFit P10 range of nasal pillows masks in the United States. Last week, Fisher & Paykel cut its fiscal 2019 earnings guidance over expected legal costs from its tiff with Resmed.
Reuters11 days ago
NZ's Fisher & Paykel Healthcare files patent infringement complaint against ResMed
Medical device maker Fisher & Paykel Healthcare said on Tuesday it had filed a patent infringement complaint in the United States against ResMed . The company said it sought an exclusion order from the ...
Reuters19 days ago
NZ's Fisher & Paykel cuts FY guidance on ResMed-linked legal costs
New Zealand medical device firm Fisher & Paykel Healthcare Corp cut its fiscal 2019 net profit outlook on Monday on the back of expected legal costs to contest patent allegations made by ResMed Inc. The firm said it would contest the patent allegations made against it by ResMed in the U.S. International Trade Commission (ITC) and U.S. District Court for the Southern District of California.
Business Wire21 days ago
ResMed Files Patent Infringement Action against Fisher & Paykel
.@ResMed files patent infringement action against Fisher & Paykel
Zacks25 days ago
Tap the Sleep Apnea Devices Market Boom With These 3 Stocks
Consider these three stocks in the sleep apnea devices market for grand returns.
Business Wire25 days ago
ResMed’s Astral Life Support Ventilator Now Has AutoEPAP in U.S.
Other upgrades include easy interface switching and program naming to improve ease of use
GuruFocus.comlast month
ResMed Inc (RMD) Files 10-K for the Fiscal Year Ended on June 30, 2018
ResMed Inc (NYSE:RMD) files its latest 10-K with SEC for the fiscal year ended on June 30, 2018. ResMed Inc is a part of the healthcare sector.
Simply Wall St.last month
What Do Analysts Think About ResMed Inc’s (NYSE:RMD) Growth?
In June 2018, ResMed Inc (NYSE:RMD) released its earnings update. Generally, analysts seem highly optimistic, as a 56.80% rise in profits is expected in the upcoming year, compared with theRead More...
Markitlast month
See what the IHS Markit Score report has to say about ResMed Inc.
ResMed Inc NYSE:RMD
Thomson Reuters StreetEvents2 months ago
Edited Transcript of RMD earnings conference call or presentation 2-Aug-18 8:30pm GMT
Q4 2018 Resmed Inc Earnings Call
Motley Fool2 months ago
ResMed Bumps Its Dividend Payment After a Solid End to Its Fiscal Year
Revenue and profits continue to grow at double-digit rates.
Zacks2 months ago
ResMed (RMD) Q4 Earnings & Sales Beat on Overall Growth
ResMed (RMD) sees solid contributions from domestic and international businesses in Q4.
Zacks2 months ago
ResMed (RMD) Q4 Earnings and Revenues Top Estimates
ResMed (RMD) delivered earnings and revenue surprises of 5.56% and 1.18%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Associated Press2 months ago
ResMed: Fiscal 4Q Earnings Snapshot
The San Diego-based company said it had profit of 76 cents per share. Earnings, adjusted for amortization costs and non-recurring costs, were 95 cents per share. The results topped Wall Street expectations. ...
Business Wire2 months ago
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2018
SAN DIEGO-- -- Revenue increased 12% to $623.6 million; up 10% on a constant currency basis Net income increased by 8%; non-GAAP net income up 24% GAAP diluted earnings per share of $0.76; non-GAAP diluted earnings per share of $0.95 Operating cash flow of $129.4 million in the fourth quarter Quarterly dividend increased by 6% to $0.37 per share ResMed Inc. today announced results for its quarter ended ...
Zacks2 months ago
Why Earnings Season Could Be Great for ResMed (RMD)
ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks2 months ago
Medical Product Earnings Lineup for Aug 2: ABC, BDX & More
Strong R&D focus is likely to be the key driver of the Medical Product space in Q2.
Zacks2 months ago
Can Overall Growth Drive ResMed's (RMD) Q4 Earnings?
ResMed (RMD) is likely to keep its winning streak alive with a gain from strong performances on the domestic as well as global front in Q4.
ACCESSWIRE2 months ago
Free Pre-Market Technical Recap on ResMed and Three Additional Healthcare Stocks
On Thursday, July 19, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: OraSure Technologies Inc. (NASDAQ: OSUR), ResMed Inc. (NYSE: RMD), OpGen Inc. (NASDAQ: OPGN), and Organovo Holdings Inc. (NASDAQ: ONVO). On Thursday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. recorded a trading volume of 373,287 shares.
Markit2 months ago
See what the IHS Markit Score report has to say about ResMed Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding RMD totaled $1.12 billion.
CNBC Videos2 months ago
President of ResMed on the outlook of his company
Medical device firm ResMed reported its fourth-quarter earnings. The company's president, Rob Douglas, weighs in on the company's performance and business strategy moving forward.